PAHO/WHO | Pan American Health Organization

PAHO strengthens birth defect surveillance with interactive regional repository

PAHO strengthens birth defect surveillance with interactive regional repository

Cristina Mitchell

25 Jun 2025

PAHO strengthens birth defect surveillance with interactive regional repository

Cristina Mitchell

25 Jun 2025

1 month 3 weeks ago

Health

Using telemedicine to manage your diabetes

Managing diabetes is a lifelong responsibility that requires consistency, regular monitoring, and reliable support. However, for many Jamaicans, juggling everyday obligations, such as work, caregiving, and long commutes, makes it difficult to...

Managing diabetes is a lifelong responsibility that requires consistency, regular monitoring, and reliable support. However, for many Jamaicans, juggling everyday obligations, such as work, caregiving, and long commutes, makes it difficult to...

1 month 3 weeks ago

Health

What’s in a psilocybin retreat?

With ‘magic mushrooms’ legally cultivated and available in Jamaica, a supportive cottage industry – psilocybin retreats for persons battling severe mood and behavioural conditions – has proven fertile ground in the transformational well-being of...

With ‘magic mushrooms’ legally cultivated and available in Jamaica, a supportive cottage industry – psilocybin retreats for persons battling severe mood and behavioural conditions – has proven fertile ground in the transformational well-being of...

1 month 3 weeks ago

Health

Healthcare quality: A rewarding return on investment

Investing in healthcare quality is not an optional expense, it’s a strategic decision that yields both financial and clinical returns. When quality is neglected, the consequences are clear: inefficient operations, patient harm, reputational damage...

Investing in healthcare quality is not an optional expense, it’s a strategic decision that yields both financial and clinical returns. When quality is neglected, the consequences are clear: inefficient operations, patient harm, reputational damage...

1 month 3 weeks ago

Health

Guiding hands across generations

WHEN 22-year-old Ashley O’Connor reflects on the person who helped shape her into the woman she is today, her voice softens with gratitude. “I have never felt a greater peace until my second mom came into my life,” said the young Kingston native. O...

WHEN 22-year-old Ashley O’Connor reflects on the person who helped shape her into the woman she is today, her voice softens with gratitude. “I have never felt a greater peace until my second mom came into my life,” said the young Kingston native. O...

1 month 3 weeks ago

Health

Jamaica launches first-ever Health Labour Market Analysis

WITH THE leadership of the Ministry of Health and Wellness (MOHW), through its Policy, Planning and Development Division, Jamaica launched its first Health Labour Market Analysis (HLMA), marking a major step forward in efforts to strengthen the...

WITH THE leadership of the Ministry of Health and Wellness (MOHW), through its Policy, Planning and Development Division, Jamaica launched its first Health Labour Market Analysis (HLMA), marking a major step forward in efforts to strengthen the...

1 month 3 weeks ago

PAHO/WHO | Pan American Health Organization

El Comité Ejecutivo de la OPS inicia su 176ª sesión abordando temas clave para la salud en las Américas

PAHO Executive Committee kicks off 176th session, addressing key health issues in the Americas

Cristina Mitchell

23 Jun 2025

PAHO Executive Committee kicks off 176th session, addressing key health issues in the Americas

Cristina Mitchell

23 Jun 2025

1 month 3 weeks ago

PAHO/WHO | Pan American Health Organization

Tobacco control efforts protect 6.1 billion people – WHO’s new report

Tobacco control efforts protect 6.1 billion people – WHO’s new report

Cristina Mitchell

23 Jun 2025

Tobacco control efforts protect 6.1 billion people – WHO’s new report

Cristina Mitchell

23 Jun 2025

1 month 3 weeks ago

Health – Dominican Today

Reinventing patient experience: Plaza de la Salud’s new management study model

After years of observing and moving through the halls of Plaza de la Salud Hospital in Santo Domingo, I have arrived at several conclusions that may prove useful to enhance healthcare services for our population. Founded by former President Joaquín Balaguer by decree in 1996—and opened its doors in 1997—this institution addressed critical gaps in our national health system.

Over the decades, it has become both an oasis and a lifeline for Dominicans, operating under a public–private, self-sustaining model that grants it a measure of operational freedom.

A recent three-day hospital stay for surgery allowed me to study in depth the pre-operative, operative and inpatient phases. Since 2010, I have applied my hospitality-sector expertise to hospital operations, refining concepts, tools and methods that may translate into meaningful improvements here and at other Dominican institutions—always mindful of our country’s specific context and resource constraints.

During my stay, I noted four key priorities:

  1. Reliable clinical protocols
    Every step of care—from post-surgical treatment plans and medication administration to vital signs checks, diagnostic tests, regular physician rounds and specialist consultations—must follow standardized procedures. Consistency in these processes underpins patient safety and trust.
  2. Staff professionalism and training
    The competence of nurses, physicians and support personnel shapes patients’ morale and engagement. When staff demonstrate expertise and clear communication, patients feel secure in their recovery journey.
  3. Appropriate medical technology
    Modern diagnostic equipment and information systems must support rapid, accurate evaluations. Access to advanced imaging and laboratory tools reduces delays and increases confidence in treatment decisions.
  4. Comfort and usability in patient rooms
    Quality beds, furniture, climate control, lighting, entertainment systems and bathroom facilities all contribute to a healing environment. Simple adjustments—adjustable lighting, supportive mattresses and easy-to-use call buttons—deliver tangible benefits to those in care.

I also identified core service roles that directly influence patient satisfaction:

  • Shift nurses
    Their interactions shape patients’ perceptions of kindness and responsiveness.
  • Routine-care physicians
    Regular check-ups and clear updates reassure patients and create a sense of security.
  • Specialist teams
    Their thoroughness and expertise inspire trust in complex treatments.
  • Food-service staff
    Attention to meal quality and timing provides comfort during lengthy stays.
  • Housekeeping
    Spotless rooms and equipment reinforce a sense of safety.
  • Support equipment and supplies
    Ergonomic furniture, durable linens and quality utensils attend to the basic needs of each patient.

To drive measurable improvements, I propose adapting proven service-industry models to healthcare:

  • Patient-centric experience
    Borrowing from Customer Experience (CX) principles, hospitals should treat each patient interaction as an opportunity to deliver personalized, respectful service.
  • Human-centered care
    Beyond clinical protocols, staff should recognize the emotional, financial and family stresses that accompany illness, offering empathy alongside medical treatment.
  • Service-delivery evaluation
    In hospitality and retail, satisfaction metrics guide service standards. Hospitals must define seven essential “public-health servant” skills—courtesy, empathy, responsiveness, reliability, safety, efficiency and tangible support—and measure performance against them.
  • Strategic staff training
    A tailored development plan should reach every team member—clinical, technical and support—accounting for the hospital’s unique systems and the nation’s healthcare realities. Imported training modules may require adaptation to our infrastructure, funding levels and patient demographics.

Plaza de la Salud stands as a beacon in Dominican healthcare. Yet, meeting rising expectations demands a deliberate shift toward service excellence alongside clinical quality. Our patients deserve care that restores not only their bodies but also their sense of dignity. By applying these service-management insights, we can forge a new model of patient experience—one rooted in reliability, compassion and efficiency—tailored to the Dominican Republic’s evolving health landscape.

_________________
By Roxanna Marte
Literary Agent, Cultural Manager, Writer.
Autores del Caribe Literary Agency.
Cultural Director of the CuentaRD Literary Project.

1 month 3 weeks ago

Health, Opinion

Health – Dominican Today

Medicine and AI advance together to save more lives

Santo Domingo.- In a firm commitment to providing top-level healthcare and putting technology at the service of the most vulnerable, the “Ciudad Sanitaria Dr. Luis E. Aybar” held its third Scientific Conference yesterday, focusing on the advances and challenges of modern medicine that remain to be overcome in the country.

Santo Domingo.- In a firm commitment to providing top-level healthcare and putting technology at the service of the most vulnerable, the “Ciudad Sanitaria Dr. Luis E. Aybar” held its third Scientific Conference yesterday, focusing on the advances and challenges of modern medicine that remain to be overcome in the country.

During the event, specialists agreed that medicine is undergoing a period of transformation thanks to technological advances that have contributed significantly to providing more accurate diagnoses, less invasive surgeries, and faster recoveries for patients.

The event featured the presentation of the innovative Brain Suite system. This tool combines neurosurgery with artificial intelligence to offer more accurate diagnoses and greater precision when treating delicate areas such as the brain and spine.

According to Dr. Federico Álvarez, this advanced technology combines magnetic resonance imaging and computed tomography with augmented reality glasses and a robotic arm, allowing precise surgical navigation.

“The idea is that if you have a patient in the operating room, you can see the inside of the area you’re going to treat and identify tumors, blood vessels, and safe surgical paths,” he explained.

According to Álvarez, who is also the representative of the Brainlab brand in the country, this new and innovative technology, which promises to save thousands of lives and time, will be available in the coming months at the Cardio-Neuro-Ophthalmology and Transplant Center (Cecanot), which will become the first hospital in the world to have this technology.

1 month 3 weeks ago

Health, Local

Medical News, Health News Latest, Medical News Today - Medical Dialogues |

Variability in heart rate during sleep may reveal early signs of stroke, depression or cognitive dysfunction, new study shows

New research, presented today at the European Academy of Neurology (EAN) Congress 2025, has uncovered a powerful link between nighttime heart rhythm and future health conditions, even in people with no obvious sleep problems.

New research, presented today at the European Academy of Neurology (EAN) Congress 2025, has uncovered a powerful link between nighttime heart rhythm and future health conditions, even in people with no obvious sleep problems.

The study, which was conducted at the Department of Neurology, Inselspital, the University Hospital of Bern, analysed 4,170 individuals over an observation period of 13,217 person-years, found that heart rate variability (HRV) during sleep can serve as a powerful early warning sign of future health conditions, including stroke, depression, and cognitive dysfunction.

HRV reflects the fluctuation of time intervals between heartbeats. HRV adjusts constantly in response to physical and emotional demands of the body. During the day, HRV is physiologically high corresponding to high levels of activity. At night, and especially during deep sleep, HRV typically reduces, reflecting a shift into a rest and repair mode, where the body focuses on recovery and recharging for the next day.

The research found that certain HRV patterns were linked to future health conditions. Participants who later developed stroke often showed unusually high and erratic HRV. In contrast, low HRV was common in those who further developed depression. High HRV with altered frequency patterns were also observed in individuals who later developed metabolic diseases. Similarly, cardiovascular and endocrine diseases were also associated with high HRV.

“HRV matters for brain and overall health because it reflects how well the body regulates itself – primarily through the activity of the autonomic nervous system”, explained the lead author of the study, Irina Filchenko, MD, PhD. “This system controls vital unconscious processes such as breathing, digestion and muscle tone, helping the body maintain balance and adapt to internal and external demands.”

“While many people are familiar with tracking sleep stages or total sleep time, nocturnal HRV provides a unique window into how the body functions during sleep. This is especially important because sleep is a critical time for many physiological processes underlying long-term health, such as cellular repair, memory consolidation, and the clearance of metabolic waste from the brain.”

Importantly, researchers believe that HRV could act as an early physiological marker, demonstrating subtle changes in body functioning before traditional symptoms or diagnoses appear. This could open the door to prevention and early intervention for diseases like Alzheimer's or stroke, where timely action can improve patient outcomes.

Dr Filchenko noted, “Some participants had ‘normal’ sleep according to traditional criteria, with little sleep fragmentation and the expected balance of sleep stages. However, HRV told a different story, picking up risks that the common sleep metrics missed. This suggests we need to rethink how we define and measure optimal sleep.”

The findings of the study also raise the possibility of using wearable technology to monitor HRV patterns over time. While current consumer devices vary in accuracy and interpretability, experts believe future improvements could allow people to track changes in HRV as part of regular health monitoring.

The research adds to growing evidence that sleep is a critical pillar of long-term health, and that subtle patterns could offer a window of opportunity to prevent serious disease. “The broader message is that sleep is not just a passive state of rest-it is an active, dynamic process that plays a vital role in maintaining long-term health, especially brain health. Our findings reinforce the idea that primary prevention matters, and that health problems start long before the clinical symptoms appear”, concluded Dr Filchenko.

Reference:

Variability in heart rate during sleep may reveal early signs of stroke, depression or cognitive dysfunction, new study shows, Beyond, Meeting: European Academy of Neurology (EAN) Congress 2025.

1 month 3 weeks ago

Neurology and Neurosurgery,Psychiatry,Neurology & Neurosurgery News,Psychiatry News,Top Medical News,Latest Medical News

Medical News, Health News Latest, Medical News Today - Medical Dialogues |

Imbruvica gets positive EMA Committee opinion for untreated mantle cell lymphoma eligible for Stem Cell Transplant: Janssen-Cilag International

Beerse: Janssen-Cilag International NV, a Johnson & Johnson company, has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending approval for an ind

Beerse: Janssen-Cilag International NV, a Johnson & Johnson company, has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending approval for an indication extension of IMBRUVICA (ibrutinib) in frontline mantle cell lymphoma (MCL).

Ibrutinib is a once-daily oral medication that is jointly developed and commercialised by Janssen Biotech, Inc. and Pharmacyclics LLC, an AbbVie company. Ibrutinib blocks the BTK protein, which is needed by normal and abnormal B-cells, including specific cancer cells, to multiply and spread. By blocking BTK, ibrutinib may help move abnormal B-cells out of their nourishing environments and inhibits their proliferation.

The recommendation is for ibrutinib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (ibrutinib + R-CHOP) alternating with R-DHAP (or R-DHAOx)* without ibrutinib, followed by ibrutinib monotherapy, for the treatment of adult patients with previously untreated MCL who would be eligible for autologous stem cell transplant (ASCT). The extended indication is based on data from the pivotal Phase 3 TRIANGLE study.

“The CHMP recommendation is an important milestone for patients with previously untreated MCL, an aggressive disease which requires complex and challenging treatment,” said Ester in’t Groen, EMEA Therapeutic Area Head Haematology, Johnson & Johnson Innovative Medicine. “We are excited by the innovation that ibrutinib continues to bring and hope to soon offer patients this frontline option that has demonstrated improved overall survival without the burden, toxicity and time in hospital associated to an ASCT-based treatment regimen.”

The CHMP recommendation for ibrutinib is supported by data from the randomised Phase 3 TRIANGLE study, conducted by the European MCL Network ( NCT02858258 ), which evaluated 870 patients across three treatment arms to assess whether the addition of ibrutinib to chemotherapy with or without ASCT could improve outcomes and potentially remove the need for transplant in patients with previously untreated MCL who were suitable for high-dose treatment. The study demonstrated that adding ibrutinib to chemotherapy followed by a 2-year fixed-duration maintenance period instead of ASCT provides significantly longer overall survival and superior failure-free survival compared to the chemotherapy regimen including ASCT.

“At Johnson & Johnson, we are committed to improving outcomes for patients facing complex blood cancers,” said Jessica Vermeulen, Vice President, Lymphoma & Leukemia Disease Area Stronghold Leader, Johnson & Johnson Innovative Medicine. “The TRIANGLE study, conducted by the European MCL Network, affirms the potential emergence of a new standard of care for transplant eligible patients diagnosed with MCL and represents the first major step forward for these patients in many years. We look forward to working together to bring this transplant-free therapeutic option to the MCL community.”

MCL is a rare, aggressive form of non-Hodgkin lymphoma. The current standard of care in the frontline setting for young and fit patients is a chemotherapy regimen including ASCT, which can be associated with severe toxicities, lengthy hospital stays and high health resource utilisation. The addition of fixed-duration ibrutinib to chemotherapy offers the potential for long treatment-free remissions while avoiding the burden of stem cell transplant. If approved, ibrutinib would become the first Bruton’s Tyrosine Kinase inhibitor (BKTi) for frontline treatment of transplant eligible MCL patients.

Ibrutinib is approved in more than 100 countries and has been used to treat more than 325,000 patients worldwide. There are more than 50 company-sponsored clinical trials, including 18 Phase 3 studies, over 11 years evaluating the efficacy and safety of ibrutinib. In October 2021, ibrutinib was added to the World Health Organization’s Model Lists of Essential Medicines (EML), which refers to medicines that address global health priorities and which should be available and affordable for all.

Ibrutinib was first approved by the European Commission (EC) in 2014, and approved indications to date include:

  • As a single agent or in combination with rituximab or obinutuzumab or venetoclax for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL)
  • As a single agent or in combination with bendamustine and rituximab (BR) for the treatment of adult patients with CLL who have received at least one prior therapy
  • As a single agent for the treatment of adult patients with relapsed or refractory MCL
  • As a single agent for the treatment of adult patients with Waldenström’s macroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. In combination with rituximab for the treatment of adult patients with WM

1 month 3 weeks ago

News,Industry,Pharma News,Latest Industry News

Pages